+7 (701) 759 90 19 Лента
USD 385.42 EUR 424.58
RUB 6.00 CNY 54.31
News

Swiss researchers find graphene nanoflakes as new tool for precision medicine

20 August 2019 12:11
Share in:
Swiss researchers find graphene nanoflakes as new tool for precision medicine

GENEVA. KAZINFORM Swiss researchers have created a new compound using graphene nanoflakes for flexible drug delivery that specifically targets prostate cancer cells, a step forward in precision medicine, the Swiss National Science Foundation said on Monday.

Related news
President Tokayev honors Rabiga Syzdyk with Barys Order U.S. scientists find how brain cells regulate memories in mice study Optimistic people sleep better, longer: study

Usually, a drug is administered indiscriminately and most of it does not reach the diseased tissues. The goal of precision medicine is to increase the efficacy of therapeutic substances by delivering them only to the proper target. This requires a customized drug delivery system, Xinhua reports.

A team of researchers at the University of Zurich added different types of molecules to single nanoflakes to transform them into a customized system for drug delivery. The results are published in Chemical Science.

First, collaborators at University College London produced the graphene nanoflakes from carbon nanotubes. Then the Zurich team attached four molecules to single flakes. They succeeded in attaching four kinds of molecules to single graphene nanoflakes to imbue them with specific capacities: transporting an anticancer drug, delivering it only to certain cancerous cells, making it visible by medical imaging and prolonging its stay in the bloodstream. The team tested each functionality to verify that the new compound works as expected.

The researchers said that the graphene nanoflakes can be used as a scaffold onto which one can add customized components, a bit like Lego bricks. The technique helps first in diagnosing prostate cancer and then in ensuring that the compound is delivered to the diseased tissues. Studies performed on cultures of prostate cancer cells later showed that their division and growth were indeed halted.

However, the team said their research is currently still fundamental, and much more work will be needed to develop a new drug. The team is now experimenting with other combinations involving antibodies instead of small peptides.


Share in:
+7
Send
Employees online
Editor
Nurmaganbetova Zhanna
Nurmaganbetova Zhanna
954-048
Editor
Raushan Alzhanova
Raushan Alzhanova
954-048
Editor
Temirgaliyeva Arailym
Temirgaliyeva Arailym
954-048

Archive